The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

NCT04591431 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

400

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Gastrointestinal Cancer
Non Small Cell Lung Cancer
Other Cancer

Interventions

DRUG: Erlotinib
DRUG: Trastuzumab
DRUG: Trastuzumab emtansine
DRUG: Pertuzumab
DRUG: Lapatinib
DRUG: Everolimus
DRUG: Vemurafenib
DRUG: Cobimetinib
DRUG: Alectinib
DRUG: Brigatinib
DRUG: Palbociclib
DRUG: Ponatinib
DRUG: Vismogedib
DRUG: Itacitinib
DRUG: Ipatasertib
DRUG: Entrectinib
DRUG: Atezolizumab
DRUG: Nivolumab
DRUG: Ipilimumab
DRUG: Pemigatinib

Sponsor

Fondazione per la Medicina Personalizzata